Dublin, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The "Global Chronic Obstructive Pulmonary Disease Therapeutics Market (2023-2028) by Drug Type, Distribution Channel, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market is set for substantial growth, with estimates indicating an increase from USD 21.12 billion in 2023 to USD 33.84 billion by 2028, representing a Compound Annual Growth Rate (CAGR) of 9.89% during the forecast period.
Market Overview
COPD treatment involves a combination of drugs, lifestyle adjustments, and supportive care, including bronchodilators, corticosteroids, antibiotics, smoking cessation, pulmonary rehabilitation, and vaccination. The market is driven by the rising number of asthma patients, an increasing prevalence of chronic respiratory disorders, and the demand for home care therapy devices. However, challenges include treatment side effects and strict government regulations.
Market Dynamics
The rise in asthma patients is a significant driver, as some may develop COPD over time, increasing the demand for COPD treatments. The prevalence of chronic respiratory disorders, caused by factors like smoking and pollution, further fuels the market growth. The need for home care therapy devices, advancements in asthma treatment and technology, and increased product launches present opportunities. However, treatment side effects and strict regulations pose challenges.
Market Segmentations
The market is segmented by drug type (Bronchodilators, Combination, Corticosteroids, Microkinetic, and Phosphodiesterase Type 4 Inhibitors), distribution channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and geography (Americas, Europe, Middle-East & Africa, Asia-Pacific). Bronchodilators hold a significant market share, while Hospital Pharmacies play a crucial role in distribution.
Recent Developments
Recent developments include TatvaCare's exploration of digital therapeutics for COPD and asthma management in India and Nuance Pharma's announcement of dosing the first patient in ENHANCE - China Phase III Trial for COPD.
Companies Mentioned
- Abbott Laboratories
- Adamis Laboratories, Inc.
- Almirall
- Astellas Pharma
- AstraZeneca Plc
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Chiesi Farmaceutici S.p.A.
- CSL Behring
- Immunotek
- Mylan N.V.
- Novartis Ag
- Orion Corp.
- Pfizer Inc.
- Pulmotect, Inc.
- Sunovion Pharmaceuticals, Inc.
- Tetherex Pharmaceutical
- Teva Pharmaceutical Industries Ltd.
- United Therapeutics Corp.
- Verona Pharma plc
- Yungjin Pharm. Co., Ltd.
Conclusion
The global COPD Therapeutics market is poised for growth driven by factors like the rise in asthma patients, increased prevalence of respiratory disorders, and demand for home care therapy devices. While challenges exist, advancements in treatment and technology, as well as increased product launches, contribute to market expansion.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 209 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $21.12 Billion |
| Forecasted Market Value (USD) by 2028 | $33.84 Billion |
| Compound Annual Growth Rate | 9.8% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/krhcq4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
